Last reviewed · How we verify
PF-07265028 (pf-07265028)
PF-07265028 will be administered orally
Pf-07265028, developed by Pfizer Inc., was a discontinued drug. Its mechanism and intended indications are not publicly available due to the discontinuation of its development.
At a glance
| Generic name | pf-07265028 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | PF-07265028 will be administered orally |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
Pipeline indications
- Advanced Solid Tumors — discontinued
Common side effects
Key clinical trials
- PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumor (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07265028 CI brief — competitive landscape report
- PF-07265028 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI